Skip to main
IMUX

Immunic Inc (IMUX) Stock Forecast & Price Target

Immunic Inc (IMUX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Immunic Inc. is displaying a positive outlook due to the encouraging results from its Phase 2 trials for lead candidate vidofludimus calcium, specifically in the treatment of progressive and relapsing multiple sclerosis (MS). Results from the CALLIPER trial indicate reductions in confirmed disability worsening, along with improvements in MRI markers related to disease progression, further supported by long-term efficacy and safety data from the EMPhASIS trial. The company's strategic focus on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases is bolstered by a robust pipeline, positioning it well for advancement in pivotal trials expected by the end of 2026.

Bears say

Immunic Inc's financial outlook is hindered by significant cash burn, with quarterly research and development expenses reaching $20 million alongside general and administrative costs of $6 million, raising concerns about sustainable funding for ongoing operations. Additionally, the company’s continued reliance on capital raises, evidenced by a recent $70 million in offerings, introduces risks of further dilution that could negatively impact shareholder value. Lastly, the potential failure of its developmental candidates to meet projected peak revenue targets poses a substantial risk to the investment thesis, compounded by uncertainties around market penetration and pricing strategies.

Immunic Inc (IMUX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Immunic Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Immunic Inc (IMUX) Forecast

Analysts have given Immunic Inc (IMUX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Immunic Inc (IMUX) has a Strong Buy consensus rating as of Apr 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Immunic Inc (IMUX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.